HighTower Advisors LLC Has $143.88 Million Stock Holdings in Abbott Laboratories $ABT

Key Points

• HighTower Advisors reduced its Abbott Laboratories stake by 5.5% in the second quarter, selling 92,701 shares and retaining 1.59 million shares valued at approximately $143.9 million. Institutional investors and hedge funds own 75.18% of ABT.
• Abbott reported quarterly EPS of $1.31, beating estimates of $1.28, while revenue reached $12.59 billion, up 13% year over year. The company guided for full-year 2026 EPS of $5.45–$5.60.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $119.50. Abbott also pays a quarterly dividend of $0.63, equivalent to a 2.3% annual yield.

HighTower Advisors LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 5.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,585,681 shares of the healthcare product maker's stock after selling 92,701 shares during the period. HighTower Advisors LLC owned approximately 0.09% of Abbott Laboratories worth $143,885,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories in the fourth quarter worth approximately $25,000. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories in the 4th quarter valued at approximately $25,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories in the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at $26,000. Finally, Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Trading Down 0.0%

Shares of ABT stock opened at $108.29 on Tuesday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a market cap of $187.38 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The business's 50 day moving average is $104.74 and its two-hundred day moving average is $100.00.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories's quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories's payout ratio is presently 81.55%.

Analyst Upgrades and Downgrades

ABT has been the subject of several recent research reports. Wolfe Research upgraded Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price objective for the company in a report on Thursday, August 13th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $130.00 target price on shares of Abbott Laboratories in a research report on Friday, July 17th. Robert W. Baird began coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They set an "outperform" rating and a $121.00 price target for the company. BTIG Research lifted their price target on Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a report on Friday, July 17th. Finally, TD Cowen raised their price objective on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a "buy" rating in a research report on Tuesday, August 25th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $119.50.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.